compound semaglutide ending The GLP-1 drug shortage is over. What's next for the compounders? Semaglutide Compound – Alliant LTC

The PIONEER-6 trial primarily evaluated the cardiovascular safety of oral semaglutide (14 mg) in comparison to placebo ( 2

David J

Enter Noom GLP-1 , a suite of programs from the digital health pioneer Noom that pairs these powerhouse meds with proven behavioral science

If these side effects are frequent or severe, the body loses a significant amount of fluid and electrolytes

Evidence Summary: What the Data Suggest Several phase 2 and observational studies highlight the hepatic benefits of GLP1based treatment: Reduced liver fat: Repeated findings in imaging-based studies support this effect Lower liver enzymes: Consistent reductions in ALT/AST levels Fibrosis improvement: Promising trends in noninvasive markers, though further trials are needed While the strongest evidence comes from patients with obesity or type 2 diabetes, benefits in leaner, metabolically abnormal patients are increasingly documented, suggesting broader utility